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896Objective: For infants with single ventricle malformations undergoing staged repair, interstage mortality is re-
ported at 2% to 20%. The Single Ventricle Reconstruction trial randomized subjects with a single morphologic
right ventricle undergoing a Norwood procedure to a modified Blalock–Taussig shunt (MBTS) or a right
ventricle-to-pulmonary artery shunt (RVPAS). The aim of this analysis was to explore the associations of inter-
stage mortality and shunt type, and demographic, anatomic, and perioperative factors.
Methods: Participants in the Single Ventricle Reconstruction trial who survived to discharge after the Norwood
procedure were included (n ¼ 426). Interstage mortality was defined as death postdischarge after the Norwood
procedure and before the stage II procedure. Univariate analysis and multivariable logistic regression were
performed adjusting for site.
Results: Overall interstage mortality was 50 of 426 (12%)—13 of 225 (6%) for RVPAS and 37 of 201 (18%)
for MBTS (odds ratio [OR] for MBTS, 3.4; P<.001). When moderate to severe postoperative atrioventricular
valve regurgitation (AVVR) was present, interstage mortality was similar between shunt types. Interstage mor-
tality was independently associated with gestational age less than 37 weeks (OR, 3.9; P ¼ .008), Hispanic eth-
nicity (OR, 2.6; P ¼ .04), aortic atresia/mitral atresia (OR, 2.3; P ¼ .03), greater number of post-Norwood
complications (OR, 1.2; P ¼ .006), census block poverty level (P ¼ .003), and MBTS in subjects with no or
mild postoperative AVVR (OR, 9.7; P<.001).
Conclusions: Interstagemortality remains high at 12% and is increasedwith theMBTS comparedwith the RVPAS
if postoperative AVVR is absent or mild. Preterm delivery, anatomic, and socioeconomic factors are also important.
Avoiding preterm delivery when possible and close surveillance after Norwood hospitalization for infants with
identified risk factors may reduce interstage mortality. (J Thorac Cardiovasc Surg 2012;144:896-906)Earn CME credits at
http://cme.ctsnetjournals.org
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Abbreviations and Acronyms
AVVR ¼ atrioventricular valve regurgitation
BSA ¼ body surface area
CPR ¼ cardiopulmonary resuscitation
DHCA ¼ deep hypothermic circulatory arrest
ECMO ¼ extracorporeal membrane oxygenation
HLHS ¼ hypoplastic left heart syndrome
MBTS ¼ modified Blalock–Taussig shunt
OR ¼ odds ratio
RVEDV ¼ right ventricular end-diastolic volume
RVEF ¼ right ventricular ejection fraction
RVESV ¼ right ventricular end-systolic volume
RVPAS ¼ right ventricle-to-pulmonary artery
shunt
SVR ¼ Single Ventricle Reconstruction
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Dthe parallel circulation is eliminated through takedown of
the systemic to pulmonary artery shunt and creation of
a cavopulmonary connection. Mortality postdischarge after
the Norwood hospitalization and before the stage II proce-
dure (interstage period) is reported to be 2% to 20%.1-4
Specific risks associated with interstage mortality identi-
fied in various investigations include a diminutive ascend-
ing aorta as seen in aortic atresia, the presence of
a restrictive atrial communication, postoperative arch ob-
struction, obstructed shunt flow, pulmonary artery distor-
tion, and atrioventricular valve regurgitation (AVVR).5,6
Age at surgery, postoperative arrhythmias, airway
complications, feeding difficulties, and noncardiac disease
processes such as gastroenteritis or upper respiratory
infection also have been implicated.3,4 Compared with the
right ventricle-to-pulmonary artery shunt (RVPAS), higher
interstage mortality has been reported for the modified Bla-
lock–Taussig shunt (MBTS).7,8
The National Heart, Lung, and Blood Institute–spon-
sored Pediatric Heart Network Single Ventricle Reconstruc-
tion (SVR) trial includes the largest prospective cohort of
infants with HLHS or related single right ventricle anoma-
lies with longitudinal follow-up after the Norwood proce-
dure. The primary results of the SVR trial demonstrated
improved transplant-free survival at 12 months in those ran-
domized to receive an RVPAS at the Norwood procedure
compared with those randomized to the MBTS. Although
interstage survival was not specifically reported, the highest
incidence of transplant or death occurred between 30 days
after the Norwood procedure and the stage II procedure.9
The goal of this analysis was to determine anatomic,
surgical, and additional patient-related risk factors for inter-
stage mortality postdischarge after the Norwood procedure
and before the stage II procedure in this unique cohort. We
specifically hypothesized that infants palliated with anThe Journal of Thoracic and CaMBTS would be at increased risk of interstage death com-
pared with those palliated with an RVPAS.
MATERIALS AND METHODS
The Pediatric Heart Network SVR trial compared outcomes between
subjects randomized to RVPAS and subjects randomized to MBTS at the
time of the Norwood procedure. Details of the trial design have been re-
ported.10 The institutional review board or research ethics board at each
participating center approved the study protocol, and written informed con-
sent was obtained from parents before trial enrollment.
Study Sample
Subjects randomized in the multicenter SVR trial who survived to dis-
charge from the hospital after the Norwood procedure are included in this
analysis. Twenty-two subjects surviving the Norwood procedure, but not
discharged before the stage II procedure, were excluded from the primary
analysis because of limitations in distinguishing Norwood operative mor-
tality from interstage mortality for subjects with planned inpatient care
to stage II procedure. Two subjects whose dates of stage II procedure could
not be determined and 2 subjects whose stage II procedures were per-
formed uncharacteristically late (ie,>14 months of age) were excluded
from the primary analysis.
Study Design and Measurements
Shunt type was defined for this analysis as the shunt in place at the end
of the Norwood procedure. The surgeon had the option to modify the shunt
if anatomy was encountered that made the randomized shunt assignment
not feasible. Other than random assignment of shunt, all participants
were managed according to the standard practices at their clinical centers.
A list of all variables that were recorded and analyzed is included in Appen-
dix Table 2. In brief, before the Norwood procedure, a detailed preoperative
medical history was recorded, including demographics, patient character-
istics, and anatomic diagnosis. Operative variables included shunt type,
pharmacologic strategies, perfusion method, and additional cardiac opera-
tions. The perfusion method during circulatory support was classified into
1 of 3 categories: deep hypothermic circulatory arrest (DHCA), regional
cerebral perfusion with DHCA time of 10 minutes or less, or regional
cerebral perfusion with DHCA time greater than 10 minutes. Postoperative
data recorded for the Norwood hospitalization included procedures, serious
adverse events such as cardiopulmonary resuscitation (CPR) and use of
extracorporeal membrane oxygenation (ECMO), number of previously
described complications,11 hospital length of stay, and feeding methods
at discharge after the Norwood procedure.
Echocardiograms were obtained before and after the Norwood proce-
dure. The echocardiograms were interpreted centrally at a core laboratory
(Medical College of Wisconsin) to assess the degree of AVVR (none/mild
vs moderate/severe), to measure right ventricular end-systolic volume
(RVESV) and right ventricular end-diastolic volume (RVEDV), and to
determine fractional area change and right ventricular ejection fraction
(RVEF). The primary measure of right ventricular contractility used in
the multivariable model was right ventricular fractional area change,
because the other measures of systolic function including RVEF, RVESV,
and RVEDV could not be obtained for 23% of the subjects. In the 330 sub-
jects for whom both measurements were available, there was a high degree
of correlation (R ¼ 0.89) between the RVEF and the right ventricular frac-
tional area change.
A subgroup of subjects consented for evaluation by a geneticist. Genetic
evaluations performed for clinical indications were also recorded. Subjects
were classified as to whether a specific genetic syndromewas identified and
whether ‘‘other abnormalities’’ (ie, not identified with a syndrome) were
present.
Socioeconomic status at the time of randomization was assigned using
a US census–based score derived from 6 measures based on income, hous-
ing, and occupational-related features of the subject’s census block tract, asrdiovascular Surgery c Volume 144, Number 4 897
TABLE 1. Associations of interstage death, site adjusted
Variables n Responses
Interstage survivals
(N ¼ 376)
Interstage deaths
(N ¼ 50) df
Site adjusted
OR P
Site 426 – – – 14
Shunt 426 376 50 1 <.001
RVPAS 212 (56) 13 (26)
MBTS 164 (44) 37 (74) 3.44
Demographic characteristics
Hispanic 421 371 50 1 .07
No 305 (82) 33 (66) –
Yes 66 (18) 17 (34) 1.99
US census% below poverty level
Tertiles 409 – 364 45 2 .006
– <5.42% 131 (36) 5 (11) – 0.38
– 5.42%-13% 113 (31) 23 (51) – 1.73
– 13% 120 (33) 17 (38) – –
US census socioeconomic score 409 0.32  5.1 1.4  4.4 1 0.95 .13
Baseline characteristics
Gestational age (wk) 426 38.3  1.5 37.7  1.9 1 0.80 .02
Preterm (gestational age<37 wk) 426 376 50 1 .01
37 wk 344 (91) 40 (80) –
<37 wk 32 (9) 10 (20) 2.81
Birth weight (kg) 426 3.2 (0.5) 3.0 (0.5) 1 0.57 .05
AA/MA 426 376 50 1 .20
No 235 (62) 26 (52) –
Yes 141 (38) 24 (48) 1.49
Norwood hospitalization
Age at Norwood (d) 426 5.6  3.7 6.5  5.1 1 1.06 .11
Norwood length of stay (d) 426 28.9  19.0 36.2  33.3 1 1.01 .03
Perfusion strategy 422 373 49 2 .19
DHCA only 211 (57) 28 (57) 0.34
RCP only or RCP/DHCA time  10 min 91 (24) 8 (16) 0.38
RCP and DHCA time>10 min 71 (19) 13 (27) –
Complications and serious adverse events during
Norwood hospitalization
No. of complications post-Norwood 426 2.08  2.1 3.58  3.4 1 1.22 <.001
No. of medications at discharge 426 4.9  1.7 5.6  2.2 1 1.15 .098
Feeding status at discharge post-Norwood
Any oral feeding 426 376 50 1 <.001
No 71 (19) 20 (40) –
Yes 305 (81) 30 (60) 0.28
Feeding category (4 df) 426 376 50 4 <.001
No oral, G or GJ tube 47 (13) 8 (16) 1.68
No oral, NG or NJ tube 24 (6) 12 (24) 8.40
Oral and G or GJ tube 19 (5) 2 (4) 1.52
Oral and NG or NJ tube 159 (42) 15 (30) 0.88
Only oral 127 (34) 13 (26) –
Echocardiography pre-Norwood
AVVR 417 370 47 1 .004
None/mild 333 (90) 35 (74) –
Moderate/severe 37 (10) 12 (26) 3.15
Ascending aorta diameter (R301), cm
pre-Norwood
414
Median cutoff 414 368 46 1 .008
<0.3 cm 172 (47) 30 (65) 2.44
0.3 cm 196 (53) 16 (35) –
(Continued)
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TABLE 1. Continued
Variables n Responses
Interstage survivals
(N ¼ 376)
Interstage deaths
(N ¼ 50) df
Site adjusted
OR P
Echocardiography post-Norwood
RV end-diastolic volume/BSA1.3 (mL/m2.6) 330 91.2  25.2 98.3  32.8 1 1.01 .14
RV end-systolic volume/BSA1.3 (mL/m2.6) 330 48.7  17.0 56.6  23.2 1 1.02 .03
RVEF (%) 330 47.3  8.0 43.2  7.3 1 0.94 .01
RV fractional area change (%) 409 37.0  7.7 34.9  6.8 1 0.97 .12
AVVR grade 423 374 49 1 .06
None/mild 297 (80) 32 (65) –
Moderate/severe 77 (20) 17 (35) 1.87
Reversal of pulmonary vein flow 384 337 47 1 .18
No 285 (85) 44 (94) –
Yes 52 (15) 3 (5) 0.46
Interaction
Atrioventricular valve insufficiency by shunt 1 .009
None/mild
MBTS 126 (82) 27 (18) 6.71 <.001
RVPAS 171 (97) 5 (3)
Moderate/severe
MBTS 37 (80) 9 (20) 1.04 .94
RVPAS 40 (83) 8 (17)
Analyses were performed using logistic regression. Frequency and percent are provided for categoric variables; mean and standard deviations are presented for continuous vari-
ables. Firth’s adjustment was used if the model fit was questionable. Discharge feeding categories were excluded from the model in favor of any oral feeding at discharge. Only
associations with a P<.20 are included in the table. For the interaction term, the ORs and P values of shunt type by atrioventricular valve insufficiency are provided. df, Degrees of
freedom;OR, odds ratio; RVPAS, right ventricle-to-pulmonary artery shunt;MBTS, modified Blalock–Taussig shunt; AA/MA, aortic atresia/mitral atresia;DHCA, deep hypother-
mic circulatory arrest; RCP, regional cerebral perfusion;G, gastrostomy,GJ, gastric-jejunal; NG, nasogastric; NJ, nasojejunal; AVVR, atrioventricular valve repair; RV, right ven-
tricle; BSA, body surface area; RVEF, right ventricular ejection fraction.
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ject’s census block tract.12
Statistical Methods
Descriptive statistics presented include median with interquartile range
for skewed variables, mean and standard deviation for other continuous var-
iables, and frequency with percentage for categoric variables. Tertiles of
continuous measures were fit to determinewhether the association between
predictor and outcome was nonlinear. Dichotomies were also explored.
Univariate logistic regression and logistic regression adjusted for site
were used to obtain initial estimates of association between interstage sur-
vival and each candidate predictor. Predictors significant at P less than .20
at the univariate or site-adjusted level were included in the multivariable
modeling. Multivariable models were developed using stepwise logistic re-
gression with bootstrap bagging 1000 samples to determine the reliability
of each individual predictor. The small number of events made the boot-
strapping procedure unstable when site (14 degrees of freedom) was a can-
didate predictor; thus, the annual center volume of screened patients with
a single right ventricle and planned Norwood procedure was included as
a surrogate for site in bootstrapping models. A predictor was retained in
the final site-adjusted multivariable model if bootstrapping reliability
was greater than 45% and its P value was less than .05.
To determine whether some prespecified factors had differential associ-
ations dependent on shunt type, interaction terms were explored. Specifi-
cally, interactions of shunt type with birth weight (<2.5 vs 2.5 kg), low
gestational age (<37 weeks), ethnicity, obstructed pulmonary venous re-
turn, presence of aortic atresia, pre-Norwood and post-Norwood AVVR,
and ECMO or CPR during the Norwood hospitalization were examined
for their association with interstage death or transplant. After the multivari-
able model main effects were determined, the significant interactions were
added and retained if significant at a P value less than .05.The Journal of Thoracic and CaIn an exploratory analysis, the multivariable model was developed using
the same approach, but after imputing missing values of RVEF, RVESV in-
dexed to body surface area (BSA)1.3, and RVEDV indexed to BSA1.3. Sim-
ple regression imputation was used for RVEF, which had 23% of the data
missing at random.Right ventricular fractional area changewas used to pre-
dict RVEF. For 17 subjects (4%) whoweremissing bothmeasurements and
for subjects missing RVESVor RVEDV, mean imputation was used. These
imputed predictors were included in the model selection process. All anal-
yses were conducted using SAS version 9.2 (SAS Institute, Inc, Cary, NC).RESULTS
Study Sample
Of the 549 subjects who were randomized in the SVR
trial and underwent the Norwood procedure, 97 died
(88) or underwent heart transplantation (9) during the Nor-
wood hospitalization, 22 remained as inpatients until the
stage II procedure, and 430 were discharged before the
stage II procedure (Figure 1). The 22 subjects who sur-
vived the Norwood procedure and were not discharged be-
fore the stage II procedure differed from those who were
discharged before the stage II procedure in that hospital-
ized subjects had a higher rate of ECMO, CPR, moderate
or greater AVVR, and postoperative complications (Ap-
pendix Table 3). Four subjects discharged were excluded
from the analysis because of an uncharacteristically late
stage II procedure (n ¼ 2) or unknown timing of the stage
II procedure (n ¼ 2). The remaining 426 subjects wererdiovascular Surgery c Volume 144, Number 4 899
FIGURE 1. Subject participation status from randomization through the interstage period. A total of 430 subjects were discharged after the Norwood
procedure. Four of these subjects were excluded because of an unusually late or missing date of the stage II procedure.
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analytic cohort. No subject discharged after the Norwood
procedure underwent heart transplantation before the stage
II procedure.TABLE 2. Multivariable model of predictors of interstage mortality with
Predictor
Died/hea
No
Site –
AVVR grade by shunt
None/mild
MBTS 117 (84)
RVPAS 165 (97)
Moderate/severe
MBTS 33 (79)
RVPAS 39 (83)
Low gestational age (<37 wk)
Yes 30 (75)
No 324 (90)
Hispanic
Yes 63 (79)
No 291 (91)
AA/MA
Yes 134 (85)
No 220 (91)
No. of complications post-Norwood and predischarge
Mean  SD 2.0  2.0
US Census percentage below poverty level tertiles
<5.42 128 (96)
5.42-13.0 109 (83)
13.0 117 (87)
Site 19 was excluded from this analysis because all 3 subjects from this site survived and re
MBTS, modified Blalock–Taussig shunt; RVPAS, right ventricle-to-pulmonary artery shunt;
plant among subjects in the<5.42 tertile compared with subjects in the 5.42-13.0 tertile.
900 The Journal of Thoracic and Cardiovascular SurgInterstage Survival
Of the 426 interstage subjects, 376 (88%) survived to the
stage II procedure. Interstage survival was higher in sub-
jects who received the RVPAS (212/225; 94%) comparedsite adjustment: N ¼ 399 (adjusted R2 ¼ 0.35)
rt transplant? Odds ratio
(95% CI)
Model
P valueYes
– – .823
– .03
23 (16) 9.7 (3.1-30.3) Contrast<.001
5 (2.9) –
9 (21) 1.4 (0.4-5.0) Contrast .57
8 (17)
10 (25) 3.9 (1.4-10.8) .008
35 (10)
17 (21) 2.6 (1.1-6.5) .04
28 (8.7)
23 (15) 2.3 (1.1-5.0) .03
22 (9.1)
3.2  3.3 1.2 (1.1-1.4) .006
.003
5 (4) 0.38 (0.12-1.3) .15 (0.05-0.48)*
23 (17) 2.5 (1.02-6.0) –
17 (13) –
nder the model unstable. CI, Confidence interval; AVVR, atrioventricular valve repair;
AA/MA, aortic atresia/mitral atresia; SD, standard deviation. *Odds of mortality/trans-
ery c October 2012
FIGURE 2. Kaplan–Meier plot of interstage survival by shunt type: Inter-
stage survival, defined as percentage alive postdischarge after the Norwood
procedure and before the stage II surgery, was significantly better for sub-
jects with an RVPAS than for subjects with an MBTS. MBTS, Modified
Blalock–Taussig shunt; RVPAS, right ventricle-to-pulmonary artery shunt.
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odds ratio (OR) for interstage mortality for the MBTS ver-
sus the RVPAS was 3.4 (95% confidence interval, 1.8-6.6;
P<.001) (Figure 2). Of the subjects who died during the in-
terstage period, the mean time to death postdischarge after
the Norwood procedure was earlier in the MBTS group (1.7
 1.6 months vs 2.8  1.5 months postdischarge after the
Norwood procedure, P<.001), with a mean age at death
3.0 2.0 months in the MBTS group and 4.3 1.7 months
in the RVPAS group (P ¼ .01). The stage II procedure was
performed at similar ages for the 2 shunt types (5.5  1.7
months vs 5.3  1.6 months, P ¼ .34).Risk Factors for Interstage Mortality
Univariate analysis. Univariate analysis was performed to
assess the association of each potential risk factor with in-
terstage mortality (Table 1). In addition to the MBTS, youn-
ger gestational age, census tract block with 5.4% to 13% of
inhabitants below federal poverty level, ascending aorta di-
ameter less than 3 mm, longer Norwood hospital length of
stay (median, 25; interquartile range, 17 to 44 days vs 23
days; interquartile range, 16-36), greater number of postop-
erative complications, and failure to feed orally before hos-
pital discharge were associated with interstage mortality.
The risk of interstage mortality was also higher in subjects
without any oral feeding with a nasal enteral tube compared
with a gastrostomy tube (OR, 5.0; 95% confidence interval,
1.5-17.1; P ¼ .01). Moderate to severe postoperative
AVVR, lower RVEF, and greater RVESV indexed toThe Journal of Thoracic and CaBSA1.3 measured on post-Norwood echocardiograms (per-
formed 15  10 days after the Norwood procedure) were
each associated with interstage mortality. Site was not a sig-
nificant predictor of interstage mortality (P ¼ .16). Genetic
syndrome and nonsyndromic comorbidities also were not
associated with interstage mortality.
Of the prespecified factors, only the interaction of shunt
type and postoperative AVVR was significantly associated
with interstage mortality (P ¼ .009). After adjustment for
site, the influence of shunt type varied with degree of
AVVR. In subjects with postoperative none/mild AVVR, in-
terstage mortality was significantly higher for the MBTS
group (MBTS 18% vs RVPAS 3%; P< .001; OR, 6.7).
However, for subjects with postoperative moderate/severe
AVVR, the overall rate of interstage mortality was similar
between the shunt types (MBTS 20% vs RVPAS 17%;
P ¼ .94; OR, 1.0).
Multivariable analysis. Independent predictors of inter-
stage mortality with adjustment for site determined through
multivariable modeling (adjusted R2 ¼ 0.35) included ges-
tational age less than 37 weeks (OR, 3.9; P ¼ .008), His-
panic ethnicity (OR, 2.6; P ¼ .04), census block poverty
level (P ¼ .003), presence of aortic and mitral atresia
(OR, 2.3; P ¼ .03), MBTS in subjects with postoperative
none/mild AVVR (OR, 9.7; P<.001), and greater number
of post-Norwood complications (OR, 1.2, per complication;
P¼ .006). With respect to census block poverty levels, sub-
jects in communities with 5.4% to 13% poverty had
a greater risk of interstage mortality compared with subjects
in the more affluent communities (OR, 6.7) and the poorest
communities (OR, 2.5) (Table 2). The exploratory analysis
that included imputed missing values of RVEF, RVESV,
RVEDV, and RV fractional area change showed that these
potential predictors were not independent risk factors of in-
terstage mortality.
DISCUSSION
This is the first multicenter prospective report of interstage
mortality for infants with HLHS and other single right ventri-
cle anomalies undergoing staged repair.The overall interstage
mortality rate of 12% from this large cohort is similar to that
of multiple prior single-center case series.1,3,4,7,8,13
Subjects who had an MBTS were at higher risk for inter-
stage mortality than those with RVPAS. With pulmonary
blood flow occurring only during systole after palliation
with theRVPAS, a higher diastolic pressure and lower pulmo-
nary to systemic flow ratio has been observed.14,15 Although
we are unable to determine the mechanisms of interstage
death in this population, it is possible that the higher
diastolic pressure associated with RVPAS contributes to
improved coronary and systemic perfusion, providing
advantageous hemodynamic stability during periods of
stress such as illness or feeding difficulties. Patients with an
MBTS may have a higher risk for acute shunt thrombosis;rdiovascular Surgery c Volume 144, Number 4 901
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death was not examined in this analysis.
Although only shunt type was randomized in the SVR
trial, the sample size and prospective data collection al-
lowed for evaluation of other potential predictors of inter-
stage mortality. Previous reports have implicated
anatomic diagnosis, residual or recurrent lesions, arrhyth-
mias, subject specific characteristics, acquired illness,
and, more recently, shunt type as risk factors for interstage
death.1,3-8,13 Although Jonas and colleagues5 found the
combination of aortic atresia with mitral stenosis to be asso-
ciated with interstage mortality for infants with HLHS,5
other investigators reviewing single-center series have not
found this anatomic variant to be a risk factor.4,16 In the
SVR cohort, only aortic atresia combined with mitral
atresia was independently associated with interstage
mortality. Aortic atresia with mitral stenosis was not
associated with worsened interstage survival for the cohort
as a whole or for either shunt group.
Single-center comparisons of subjects with the RVPAS
versus the MBTS have reported no observable differences
in myocardial performance and ventricular volumes before
the stage II procedure.17,18 Although measurable
differences in RVEF and RVESV indexed for BSA were
observed between shunt types before discharge after the
Norwood procedure, these echocardiographic findings were
not independent risk factors for interstage mortality.
Previous studies have identified postoperative moderate/
severe AVVR as a risk factor for interstage mortality. In the
current analysis, shunt type was a predictor of interstage
mortality when there was mild or no postoperative AVVR.
However, when postoperative AVVR was moderate or
greater, there was no selective benefit of the RVPAS and
both shunt groups had higher mortality rates compared with
subjects with mild or no AVVR and an RVPAS. These data
suggest that the higher interstage mortality risk for the
MBTS is not a consequence of greater AVVR. Moderate to
severe AVVR does increase the risk of interstage mortality,
possibly secondary to the additional volume load and
ineffective ventricular output that can be exacerbated by
conditions that elevate systemic vascular resistance.
We found that gestational age less than 37 weeks was an
independent risk factor for interstage mortality. Given the
high correlation of gestational age with birth weight, it is
not surprising that birth weight was not found to be a sepa-
rate independent risk factor. In a series comparing outcomes
after cardiac surgery for term and preterm infants, compli-
cations of prematurity and postoperative mortality were
common in preterm infants, illustrating the added vulnera-
bility of preterm subjects.19 Other studies have identified
extracardiac anomalies as a risk factor for mortality in sub-
jects with HLHS.20,21 Extracardiac anomalies were not
associated with increased risk in our cohort, but this may
be confounded by a greater tendency for subjects with902 The Journal of Thoracic and Cardiovascular Surgextracardiac malformations to die before hospital
discharge. Furthermore, although use of an RVPAS has
been advocated in the presence of high-risk characteris-
tics,13 our analysis did not demonstrate a particular protec-
tive effect of the RVPAS for preterm or low-birth-weight
infants or for infants with extracardiac anomalies. Again,
when considering this finding, it is important to consider
that inclusion in this cohort required survival of the Nor-
wood procedure and discharge from the hospital. Thus, sub-
jects with these risks may be less likely to survive to
hospital discharge after the Norwood procedure. Delivery
at term seems to be an important and likely modifiable
risk factor. This observation is consistent with a large series
in which neonates aged less than 39 weeks with critical con-
genital heart disease had greater morbidity and interstage
mortality than infants delivered at more than 39 weeks.22
Having a higher number of postoperative complications
correlatedwith longer length of stay andwas an independent
risk factor for interstage mortality. Longer length of stay in
other series of infants with serious congenital heart disease
has been associated with negative outcomes, including early
mortality and lower scores on neurodevelopmental testing.23
Poor interstage growth velocity and malnutrition are com-
mon after the Norwood procedure24,25; thus, alternative
feeding methods may be necessary to ensure adequate
nutritional support. However, the best approach to feeding
children after the Norwood procedure remains a challenge
and there is wide variation in practice patterns. Univariate
analysis showed that the absence of oral feeding before
discharge after the Norwood procedure was associated with
interstage mortality, particularly if nasogastric tube feedings
were used rather than a direct gastrostomy tube. Poor
feeding and failure to thrive in infants with congenital heart
disease, specifically single ventricle disease, may be
secondary to several mechanisms, such as decompensated
heart failure, airway abnormalities, or gastrointestinal
dysmotility. Thus, inability to feed orally may be
a surrogate for added vulnerability in the infant with
Norwood physiology. These data suggest that for subjects
who require enteral tube feeding with complete absence of
oral feeding, discharge with a direct gastrostomy tube may
be preferable over a nasal enteral tube. The mechanism for
interstage death in those with a nasogastric tube may
include aspiration due to stenting of the lower esophageal
sphincter, impaired breathing due to nasopharyngeal
obstruction, or vagal response from reflux or gagging
leading to bradycardia-induced arrhythmias.
Interstage mortality was associated with 2 sociodemo-
graphic variables: living in a census block with 5.4%
to 13% below the poverty level and Hispanic ethnicity.
Although the finding that participants in census blocks
with lower or higher poverty levels had a lower risk of inter-
stage mortality is not intuitive, it is possible that access to
care was more limited in communities with 5.4% to 13%ery c October 2012
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access to care was not within the scope of this study, it may
be valuable to identify high-risk families with reduced ac-
cess to nearby care to develop a support network and opti-
mize interstage surveillance. Home monitoring with daily
oxygen saturations and weight measurements, and with
increased communication, has been associated with re-
duced interstage mortality in some series2,4,26 and may be
of particular value when access to pediatric cardiac care is
not readily available. Practices for home monitoring were
not standardized in the SVR trial, and its impact on
interstage mortality was not evaluated in this analysis.
Although this is the largest prospectively followed cohort
of children with HLHS and other single right ventricle
anomalies studied for risk factors for interstage mortality,
there are limitations of our investigation. There was wide
variation in practice throughout the course of this study
across the clinical sites, including inpatient management
for select patients with complicated post-Norwood hospital-
ization. Many variables evaluated in this study may be
linked, and thus the implications of some practices cannot
be defined. Furthermore, some variables deemed important
even in the multivariable models may be only surrogates for
other unmeasured variables. By adjusting for site and using
bootstrapping, we have tried to minimize bias and maxi-
mize reliability.
CONCLUSIONS
We found higher interstage mortality in subjects who re-
ceived an MBTS. However, RVPAS was only protective for
interstage mortality in those subjects with none/mild AVVR
after the Norwood procedure. Additional independent risk
factors for interstage mortality included gestational age
less than 37 weeks, Hispanic ethnicity, census block with
5.4% to 13% of inhabitants below poverty level, aortic
atresia/mitral atresia, and increased number of post-
Norwood complications. On the basis of our findings, we
recommend avoiding preterm delivery when possible and
considering close surveillance of infants discharged after
the Norwood procedure with these identified risk factors.
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APPENDIX TABLE 2. Candidate predictor list
Site
Shunt type
Baseline characteristics
Gestational age (wk)
Preterm (gestational age<37 wk)
Birth weight (kg)
Low birth weight (<2500 g)
Race (white, black, other)
Hispanic
Anatomic diagnosis (HLHS, single right ventriclewith systemic outflow,
straddling mitral valve with left ventricle hypoplasia and outflow
obstruction, other)
HLHS (yes/no)
Heterotaxy (yes/no)
Aortic atresia/mitral atresia (yes/no)
Aortic atresia/mitral stenosis (yes/no)
Aortic stenosis/mitral stenosis (yes/no)
Obstructed pulmonary venous return (yes/no)
Age at Norwood (d)
US Census Socioeconomic Index Score
US Census% below poverty level
Norwood hospitalization
Total bypass time (min)
Perfusion strategy during Norwood: DHCA only, RCP only or RCP with
DHCA no>10 min, RCP and DHCA time>10 min)
ECMO (yes/no)
Ultrafiltration during (yes/no)
Aortic atresia (yes/no)
Steroids (yes/no)
Trasylol (yes/no)
Alpha-blockade (yes/no)
CPR post-Norwood during hospital stay (yes/no)
Oxygen saturation at discharge post-Norwood (yes/no)
Norwood length of stay
No. of unintended cardiovascular procedures
Balloon dilation, stent placement, or surgical revision of the neo-aorta
(yes/no)
Pulmonary artery reconstruction (yes/no)
Balloon dilation or stenting of the shunt or branch pulmonary arteries
(yes/no)
Shunt revision or crossover (yes/no)
Atrioventricular valve repair (yes/no)
Diaphragm plication (yes/no)
Gastrostomy tube (yes/no)
Pericardial window (yes/no)
Shunt revision (no crossover)
Thoracostomy tube (yes/no)
No. of complications predischarge, post-Norwood
Any serious adverse event (yes/no)
Any oral feeding at discharge (yes/no)
Only oral feeding at discharge (yes/no)
Feeding category (gastrostomy or gastrostomy-jejunal tube, nasal gastric
or nasal jejunal tube, only oral)
Feeding category (no oral, G or GJ tube; no oral, NG or NJ tube; oral,
G or GJ tube; oral, NG or NJ tube; only oral)
No. of discharge medications
(Continued)
APPENDIX TABLE 2. Continued
Echocardiography pre-Norwood
RVEDV indexed to BSA1.3
RVESV indexed to BSA1.3
RVEF
Atrioventricular valve insufficiency (moderate to severe AVVR) at
pre-Norwood
Ascending aorta diameter (mm)
Echocardiography post-Norwood
Echo Nakata Index
Aortic valve insufficiency (not patent, no regurgitation, regurgitation)
Atrioventricular valve insufficiency at post-Norwood (none/mild vs
moderate/severe).
Right ventricular end-diastolic volume indexed to BSA1.3
Right ventricular end-systolic volume indexed to BSA1.3
RVEF
Right ventricular percent area change
Reversal of pulmonary vein flow (yes/no)
Genetic evaluations (yes at any visit)
Genetic syndrome (yes/no)
Any nonsyndromic abnormality (yes/no)
Genotype (E3/E3, E4/E4, E2/E3, E2/E4, E3/E4)
Site volume and surgeon Norwood volume
Surgeon Norwood experience, based on all screened subjects
(continuous and 4-level categories)
Site volume, based on annual center volume of Norwood procedures
(continuous and 4-level categories)
HLHS, Hypoplastic left heart syndrome;DHCA, deep hypothermic circulatory arrest;
RCP, regional cerebral perfusion; ECMO, extracorporeal membrane oxygenation;
CPR, cardiopulmonary resuscitation; G, gastrostomy, GJ, gastric-jejunal; NG, naso-
gastric; NJ, nasojejunal; RVEDV, right ventricular end-diastolic volume; BSA, body
surface area; RVESV, right ventricular end-systolic volume; RVEF, right ventricular
ejection fraction; AVVR, atrioventricular valve regurgitation.
Ghanayem et al Congenital Heart Disease
The Journal of Thoracic and Cardiovascular Surgery c Volume 144, Number 4 905
C
H
D
APPENDIX TABLE 3. Univariate comparisons of subjects who were
discharged after Norwood procedure with those who were not
discharged and survived to stage II
Characteristic
Discharged
(N ¼ 426)
Not discharged
and survived
(N ¼ 22)
P
value
Shunt .52
RVPAS 225 (53) 10 (46)
MBTS 201 (47) 12 (55)
Norwood hospitalization
Norwood length of
stay (d)
Median (IQR) 23 (16-36) 115 (67-147) <.001
Total bypass time (min)
Median (IQR) 130.0 (101.0-163.0) 152.0 (122.0-184.0) .03
Placed on ECMO <.001
No 402 (94) 13 (59)
Yes 24 (5.6) 9 (41)
Ultrafiltration during CPB .02
No 161 (38) 3 (14)
Yes 265 (62) 19 (86)
Steroids .005
No 40 (9.4) 7 (32)
Yes 386 (91) 15 (68)
CPR post-Norwood
during hospital stay
<.001
No 397 (93) 10 (45)
Yes 29 (6.8) 12 (55)
No. of unintended
cardiovascular
procedures
<.001
0 360 (85) 12 (55)
1 56 (13) 6 (27)
2 10 (2.3) 4 (18)
Balloon dilation or stenting
of the shunt or branch
pulmonary arteries
.02
No 408 (96) 18 (82)
Yes 18 (4.2) 4 (18)
Shunt revision or crossover .04
No 378 (89) 16 (73)
Yes 48 (11) 6 (27)
Shunt revision without
crossover
.002
No 411 (96) 17 (77)
Yes 15 (3.5) 5 (23)
PA reconstruction .05
No 426 (100) 21 (95)
Yes 0 (0.0) 1 (4.5)
Gastrostomy tube .002
No 357 (84) 12 (55)
Yes 69 (16) 10 (45)
Thoracostomy tube .03
No 404 (95) 18 (82)
Yes 22 (5) 4 (18)
(Continued)
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Characteristic
Discharged
(N ¼ 426)
Not discharged
and survived
(N ¼ 22)
P
value
Complications and
serious adverse events
No. of complications
Median (IQR) 2.0 (1.0-3.0) 6.0 (3.0-15.0) <.001
No. of SAEs
Median (IQR) 0.0 (0.0-0.0) 1.0 (0.0-2.0) <.001
Any SAE <.001
0 362 (85) 9 (41)
1 64 (15) 13 (59)
Feeding at discharge
Any oral feeding? <.001
No 91 (21) 18 (82)
Yes 335 (79) 4 (18)
Only oral feeding? <.001
No 286 (67) 22 (100)
Yes 140 (33) 0 (0)
Feeding category (3 df) <.001
Any oral, other tube 0 (0.0) 1 (5)
Any oral, G or GJ tube 76 (18) 12 (55)
Any oral, NG or NJ tube 210 (49) 9 (41)
Only oral 140 (33) 0 (0)
Feeding category (4 df) <.001
No oral, other tube 0 (0) 1 (5)
No oral, G or GJ tube 55 (13) 10 (45)
No oral, NG or NJ tube 36 (8) 7 (32)
Oral and G or GJ tube 21 (5) 2 (9)
Oral and NG or NJ tube 174 (41) 2 (9)
Only oral 140 (33) 0 (0)
Echocardiography
pre-Norwood
AVVR .04
None/mild 368 (88) 16 (73)
Moderate/severe 49 (12) 6 (27)
Echocardiography
post-Norwood
Akata Index
Median (IQR) 123.3
(95.5-159.0)
157.1
(120.4- 223.6)
.006
AVVR .003
None/mild 329 (78) 10 (48)
Moderate/severe 94 (22) 11 (52)
Death during stage II
hospitalization
among subjects
surviving to stage II
No 367 (98) 14 (64) <.001
Yes 9 (2) 8 (36)
With the exception of shunt type, only differences in characteristics between dis-
charged and nondischarged subjects with P< .05 are presented. Fisher exact test
was used to compare subject groups for variables that are dichotomous or categoric.
The Wilcoxon rank-sum test was used to compare subject groups for continuous vari-
ables that are skewed. Student 2-sample t test was used for continuous variables that
are not skewed. RVPAS, Right ventricle-to-pulmonary artery shunt; MBTS, modified
Blalock–Taussig shunt; IQR, interquartile range; ECMO, extracorporeal membrane
oxygenation; CPB, cardiopulmonary bypass; CPR, cardiopulmonary resuscitation;
PA, pulmonary artery; SAE, serious adverse event; G, gastrostomy; GJ, gastric-
jejunal; NG, nasogastric; NJ, nasojejunal; AVVR, atrioventricular valve regurgitation.
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